Octreotide vs KPV
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →Side-by-Side Comparison
| Aspect | Octreotide | KPV |
|---|---|---|
| Mechanism | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. |
| Typical Dosage | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. |
| Administration | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. |
| Side Effects | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. |
| Best For |
What They Have in Common
Both Octreotide and KPV are commonly used for: